Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-90002 · 1 trial · 1 indication
Number of participants with a DLT
Dose at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in Cycle 1.
Dose that is the last dose level below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during Cycle 1.
Dose at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in Cycle 1.
Dose that is the last dose level below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during Cycle 1.
| Arm | Type | Description |
|---|---|---|
| Part A: CC-90002 | EXPERIMENTAL | CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle |
| Part B: CC-90002 with Rituximab | EXPERIMENTAL | CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL |
| Name | Type | Description |
|---|---|---|
| CC-90002 | DRUG | - |
| Rituximab | DRUG | - |
Inclusion Criteria: 1. Men and women, 18 years or older, with advanced, relapsed or refractory solid tumors, Multiple Myeloma (MM) or non-Hodgkin's lymphoma (NHL) in Part A. In Part B, relapsed and/or refractory CD20-positive NHL subjects only. 2. At least one site of measurable disease in subjects...
CC-90002 is an investigational small molecule being studied for the treatment of hematologic neoplasms, which are cancers of the blood and bone marrow. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
CC-90002 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY.
CC-90002 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. Its Phase 1 trial has been completed.
CC-90002 has one completed Phase 1 clinical trial, NCT02367196, which was a dose-finding study in patients with advanced solid and hematologic cancers. The trial enrolled 60 participants and was conducted in the United States and Spain.
CC-90002 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it remains in clinical development and has not been authorized for marketing.